Therapeutic approaches to organ fibrosis

International Journal of Biochemistry and Cell Biology

Volumn 29, Issue 1, 1997, Pages 79-89

  Franklin, T J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Anti fibrotic therapy; Collagen synthesis; Cytokines; Fibrosis

Indexed keywords

ALPHA INTERFERON; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; CONNECTIVE TISSUE GROWTH FACTOR; DECORIN; ENDOTHELIN; ENZYME INHIBITOR; GAMMA INTERFERON; GROWTH FACTOR; PIRFENIDONE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN LYSINE 6 OXIDASE; PROTEINASE; RELAXIN; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG;

COLLAGEN SYNTHESIS; FIBROSIS; HUMAN; NONHUMAN; REVIEW; SCAR FORMATION; SIGNAL TRANSDUCTION;

ANIMALS; COLLAGEN; CYTOKINES; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; HUMANS; INFLAMMATION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031031973     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(96)00121-5     Document Type: Review

References (58)

1. Anderson S., Rennke H. G. and Brenner B. M. (1986) Therapeutic advantage of converting enzyme inhibitors in arresting renal disease associated with systemic hypertension. J. Clin. Invest. 77, 1993-2000.
2. Battegay E. J., Raines E. W., Seifert R. A., Bowen-Pope D. F. and Ross R. (1990) TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 63, 515-524.
3. Bella J., Brodsky B. and Berman H. M. (1995) Hydration structure of a collagen peptide. Structure 3, 393-396.
4. Benigni A., Zoja C., Corna D., Onsio S., Longaretti L., Bertani T. and Remuzzi G. (1993) A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 44, 440-444.
5. 4-induced fibrosis in the liver in rats. J. Hepatol. 13, Suppl. 3, S26-S34.
6. Bojestig M., Arnqvist H. J., Hermanson G., Karlberg B. E. and Ludvigsson J. (1994) Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N. Engl. J. Med. 330, 15-24.
7. Border W. A. and Noble N. A. (1994) Transforming growth factor-β in tissue fibrosis. N. Engl. J. Med. 331, 1286-1293.
8. Bottinger E. P., Factor V. M., Tsang M. L.-S., Weatherbee J. A., Kopp J. B., Qian S. W., Wakefield L. M., Roberts A. B., Thorgeirsson S. S. and Sporn M. B. (1996) The recombinant proregion of transforming growth factor-β1 (LAP) inhibits active transforming growth factor-β1 in transgenic mice. Proc. Natl Acad. Sci. U.S.A., in press.
9. Brattain M. G., Markovitz S. D. and Wilson J. K. V. S. (1996) Type II transforming growth factor-β receptor as a tumor suppressor gene. Curr. Opin. Oncol. 8, 49-53.
10. Brodsky B. and Shah N. K. (1995) The triple-helix motif in proteins. FASEB J. 9, 1537-1546.
11. Cambrey A. D., Harrison N. K., Dawes K. E., Southcott A. M., Black C. M., du Bois R. M., Laurent G. J. and McAnulty R. J. (1994) Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am. J. Respir. Cell. Mol. Biol. 11, 439-445.
12. Castilla A., Prieto J. and Fausto N. (1991) Transforming growth factor β1 and α1N in chronic liver disease. N. Engl. J. Med. 324, 933-940.
13. Comerci J. T., Runowicz C. D., Flanders K. C., De Victoria C. D., Fields A. L., Kadish A. S. and Goldberg G. L. (1996) Altered expression of transforming growth factor-β in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix. Cancer 77, 1107-1114.
14. Crystal R. G., Bitterman P. B., Rennard S. I., Hance A. J. and Keogh B. A. (1984) Interstitial lung diseases of unknown cause (Part 2). N. Engl. J. Med. 310, 235-244.
15. Czaja M. J., Weiner F. R. and Flanders K. C. (1989) In vitro and in vivo association of transforming growth factor-β1 with hepatic fibrosis. J. Cell. Biol. 108, 2477-2482.
16. Daopin S., Piez K. A., Ogawa Y. and Davies D. R. (1992) Crystal structure of transforming growth factor-β: an unusual fold for the superfamily. Science 257, 369-373.
17. Dennis P. A. and Rifkin D. B. (1991) Cellular activation of latent transforming growth factor-β requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc. Natl Acad. Sci. U.S.A. 88, 580-584.
18. Franklin T. J., Gregory H. and Morris W. P. (1986) Acceleration of wound healing by recombinant human urogastone (epidermal growth factor). J. Lab. Clin. Med. 108, 103-108.
19. Franklin T. J., Hales N. J., Johnstone D., Morris W. P., Cunliffe C. J., Millest A. J. and Hill G. B. (1991) Approaches to the design of antifibrotic drugs. Biochem. Soc. Trans. 19, 812-815.
20. Friedman S. L. (1993) The cellular basis of hepatic fibrosis. N. Engl. J. Med. 328, 1828-1835.
21. Gomez-Garre D., Ruiz-Ortega M., Ortego M., Largo R., Lopez-Armada M. J., Plaza J. J. and Egido J. (1996) Effects and interactions of endothelin and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 27, 885-892.
22. Granstein R. D., Flotte T. J. and Amento E. P. (1990a) Interferons and collagen production. J. Invest. Dermatol. 95, 75S-80S.
23. Granstein R. D., Rook A., Flotte T. J., Haas A., Gallo R. L., Jaffe H. S. and Amento E. P. (1990b) A controlled trial of intralesional recombinant interferon-γ in the treatment of keloidal scarring. Arch. Dermatol. 126, 1295-1302.
24. Grotendorst G. R., Okuchi H. and Hayashi N. (1996) A novel transforming growth factor β response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ. 7, 469-480.
25. Guarda E., Katwa L., Myers P. R., Tyagi S. C. and Weber K. T. (1993) Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc. Res. 27, 2130-2134.
26. Hill C. H. (1994) The design and synthesis of selective protein kinase C inhibitors. In Medicinal Chemistry: Principles and Practice, pp. 226-240. The Royal Society of Chemistry, Cambridge, U.K.
27. Isaka Y., Brees D. K., Ikegaya K., Kaneda Y., Imai E., Noble N. A. and Border W. A. (1996) Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med. 2, 418-423.
28. Ishimaru T., Kanamaru T., Takahashi T. and Okazaki H. (1988) Inhibition of prolyl hydroxylase activity and collagen biosynthesis by Fibrostatin C, a novel inhibitor produced by Streptomyces catenulae subsp. griseospora no. 23924. J. Antibiotics XLI, 1688-1694.
29. Iyer S. N., Wild J. S., Schiedt M. J., Hyde D. M., Margolin S. B. and Giri S. N. (1995) Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med. 125, 779-785.
30. Johnson R. J., Floege J., Couser W. G. and Alpers C. E. (1993) Role of platelet-derived growth factor in glomerular disease. J. Am. Soc. Nephrol. 4, 119-128.
31. Kagami S., Border W. A., Miller D. E. and Noble N. A. (1994) Angiotensin II stimulated extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J. Clin. Invest. 93, 2431-2437.
32. Karvonen K., Ala-Kokko L., Pihlajaniemi T., Helaakoski T., Henke S., Günzler V., Kivirikko K. I. and Savolainen E.-R. (1990) Specific inhibition of prolyl 4-hydroxylase and inhibition of collagen synthesis by oxaproline-containing peptides in cultured human skin fibroblasts. J. biol. Chem. 265, 8415-8419.
33. Kikuchi K., Kadono T., Sato S., Tamaki K. and Takehara K. (1995) Impaired growth response to endothelin-1 in scleroderma fibroblasts. Biochem. Biophy. Res. Commun. 207, 829-838.
34. Kon V., Hunley T. E. and Fogo A. (1995) Combined antagonism of endothelin A /B receptors links endothelins to vasoconstriction whereas angiotensin II effects fibrosis. Transplantation 60, 89-95.
35. LaBreque D. R. (1992) Hepatocyte growth factor - how do I know thee? Let me count the ways. Gastroenterology 103, 1686-1691.
36. Levitzki A. (1992) Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J. 6, 3275-3282.
37. Logan A., Berry M., Gonzalez A. M., Frautschy S. A., Sporn M. B. and Baird A. (1994) Effects of transforming growth factor β1 on scar production in the injured central nervous system of the rat. Eur. J. Neurosci. 6, 355-363.
38. Majamaa K., Turpeeniemi-Hajanen T. M., Latipää P., Günzler V., Hanauske-Abel H. M., Hassinen I. E. and Kivirikko K. I. (1985) Differences between collagen hydroxylases and 2-oxoglutarate dehydrogenase in their inhibition by structural analogues of 2-oxoglutarate. Biochem. J. 229, 127-133.
39. 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology 18, 1344-1349.
40. Matsuda Y., Matsumoto K., Ichida T. and Nakamura T. (1995) Hepatocyte growth factor suppresses the onset of liver cirrhosis and abrogates lethal dysfunction in rats. J. Biochem. 118, 643-649.
41. Pachenko M. V., Stettler-Stevenson W. G., Trubetskoy O. V., Gacheru S. N. and Kagan H. M. (1996) Metalloproteinase activity secreted by fibrogenic cells in the processing of pro-lysyl oxidase. Potential role of C-proteinase. J. biol. Chem. 271, 7113-7119.
42. Peacock A. J., Dawes K. E., Shock A., Gray A. J., Reeves J. T. and Laurent G. J. (1992) Endothelin 1 and endothelin 3 induce chemotaxis and replication of pulmonary artery fibroblasts. Am. J. Respir. Cell. Mol. Biol. 7, 492-499.
43. Prockop D. J. and Kivirikko K. I. (1995) Collagens: molecular biology, diseases and potential for therapy. Annu. Rev. Biochem. 64, 403-434.
44. Rockwell A. B., Cohen I. K. and Ehrlich H. P. (1989) Keloid and hypertrophic scars: a comprehensive review. Plast. Reconstr. Surg. 84, 827-837.
45. Rosenbloom J. and Harsch M. (1973) Hydroxyproline content determines denaturation temperature of chick tendon collagen. Arch. Biochem. Biophys. 158, 478-481.
46. 3 to cutaneous rat wounds reduces scarring. J. Cell Sci. 108, 985-1002.
47. Shah M. A., Trackman P. C., Gallop P. M. and Kagan H. M. (1993) Reaction of lysyl oxidase with trans-2-phenylcyclopropylamine. J. biol. Chem. 268, 11580-11585.
48. Suga H., Teraoka S., Ota K., Komemushi S., Furutani S., Yamauchi S. and Margolin S. B. (1995) Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp. Toxic. Pathol. 47, 287-291.
49. Terrell T. G., Working P. K., Chow C. P. and Green J. D. (1993) Pathology of recombinant transforming growth factor-β in rats and rabbits. Int. Rev. Exp. Pathol. 34, 43-67.
50. Unemori E. and Amento E. P. (1990) Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J. biol. Chem. 265, 10681-10685.
51. Unemori E., Beck L. S., Lee W. P., Xu Y., Siegel M., Keller G., Liggitt H. D., Bauer E. A. and Amento E. P. (1993) Human relaxin decreases collagen accumulation in vivo in two rodent models of fibrosis. J. Invest. Dermatol. 101, 280-285.
52. Wahl S. M., Allen J. B., Hines K. L., Imachi T., Wahl A. M., Furcht L. T. and McCarthy J. B. (1994) Synthetic fibronectin peptides suppress arthritis in rats by interrupting leukocyte adhesion and recruitment. J. Clin. Invest. 94, 655-662.
53. Wakeling A. E., Barker A. J., Davies D. H., Brown D. S., Green L. R., Cartlidge S. A. and Woodburn J. R. (1996) Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res. Treat. 38, 67-73.
54. Weber K. T., Brilla C. G. and Janicki J. S. (1993) Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc. Res. 27, 341-348.
55. Wolf G., Haberstroh U. and Nielsen E. G. (1992) Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am. J. Pathol. 140, 95-107.
56. Wu J. and Danielsson Å. (1994) Inhibition of hepatic fibrogenesis: a review of pharmacological candidates. Scand. J. Gastroenterol. 29, 385-391.
57. Yamamoto T., Nakamura T., Noble N. A., Ruoslahti E. and Border W. A. (1993) Expression of transforming growth factor-β is elevated in human and experimental nephropathy. Proc. Natl Acad. Sci. U.S.A. 90, 1814-1818.
58. Yingling J. M., Wang X.-F. and Bassing C. H. (1995) Signalling by transforming growth factor-β receptors. Biochim. Biophys. Acta 1241, 115-136.